Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial

AIMS/INTRODUCTION: In the EMPA‐REG OUTCOME(®) trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes and established cardiovascular disease. This explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Takashi, Nangaku, Masaomi, Hantel, Stefan, Okamura, Tomoo, von Eynatten, Maximilian, Wanner, Christoph, Koitka‐Weber, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497612/
https://www.ncbi.nlm.nih.gov/pubmed/30412655
http://dx.doi.org/10.1111/jdi.12971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497612/
https://www.ncbi.nlm.nih.gov/pubmed/30412655
http://dx.doi.org/10.1111/jdi.12971

Ejemplares similares